RESUMEN
Tuberculosis is a communicable disease which affects humans particularly the lungs and is transmitted mainly through air. Despite two decades of intensive research aimed at understanding and combating tuberculosis, persistent biological uncertainties continue to hinder progress. Nowadays, heterocyclic compounds have proven themselves in effective treatment of tuberculosis because of their wide range of biological and pharmacological activities. Antituberculosis or antimycobacterial agents encompass a broad array of compounds utilized singly or in conjunction to combat Mycobacterium infections, spanning from tuberculosis to leprosy. Here, we summarize the synthesis of various heterocyclic compounds which includes the greener synthetic route as well as use of nano compounds as catalyst along with their anti TB activities.
Asunto(s)
Antituberculosos , Compuestos Heterocíclicos , Pruebas de Sensibilidad Microbiana , Mycobacterium tuberculosis , Antituberculosos/farmacología , Antituberculosos/química , Antituberculosos/síntesis química , Compuestos Heterocíclicos/química , Compuestos Heterocíclicos/farmacología , Compuestos Heterocíclicos/síntesis química , Humanos , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis/tratamiento farmacológico , Estructura MolecularRESUMEN
Nowadays, the scientific community has focused on dealing with different kinds of diseases by exploring the chemistry of various heterocycles as novel drugs. In this connection, medicinal chemists identified carbonic anhydrases (CA) as one of the biologically active targets for curing various diseases. The widespread distribution of these enzymes and the high degree of homology shared by the different isoforms offer substantial challenges to discovering potential drugs. Medicinal and synthetic organic chemists have been continuously involved in developing CA inhibitors. This review explored the chemistry of different heterocycles as CA inhibitors using the last 11 years of published research work. It provides a pathway for young researchers to further explore the chemistry of a variety of synthetic as well as natural heterocycles as CA inhibitors.
Asunto(s)
Inhibidores de Anhidrasa Carbónica , Anhidrasas Carbónicas , Química Farmacéutica , Compuestos Heterocíclicos , Inhibidores de Anhidrasa Carbónica/farmacología , Inhibidores de Anhidrasa Carbónica/síntesis química , Inhibidores de Anhidrasa Carbónica/química , Compuestos Heterocíclicos/farmacología , Compuestos Heterocíclicos/química , Compuestos Heterocíclicos/síntesis química , Humanos , Anhidrasas Carbónicas/metabolismo , Anhidrasas Carbónicas/efectos de los fármacos , Relación Estructura-Actividad , Estructura Molecular , AnimalesRESUMEN
The present research focused on the tail-approach synthesis of novel extended thiazolotriazoles (8a-8j) and triazolothiadiazines (11a-11j) including aminotriazole intermediate 10. After successful synthesis, all the compounds were evaluated for their inhibition potential against cytosolic isoforms of human carbonic anhydrase (hCA I, II), tumor-linked transmembrane isoforms (hCA IX, XII), and cathepsin B. As per the inhibition data, the newly synthesized compounds showed poor inhibition against hCA I. Many of the compounds showed effective inhibition toward hCA IX and/or XII in low nanomolar concentration. Despite the strong to moderate inhibition of hCA II by these compounds, more than half of them demonstrated better inhibition against hCA IX and/or XII, comparatively. Further, insights of CA inhibition data of these extended analogs and their comparison with earlier reported thiazolotriazole and triazolothiadiazine derivatives might help in the rational design of novel potent and selective hCA IX and XII inhibitors. The novel compounds were also found to possess anti-cathepsin B potential at a low concentration of 10-7 M. Broadly, compounds of series 11a-11j presented more effective inhibition against cathepsin B than their counterparts in series 8a-8j. Moreover, these in vitro results with respect to cathepsin B inhibition were also supported by the in silico insights obtained via molecular modeling studies.
RESUMEN
The design and synthesis of a library of 21 novel benzenesulfonamide-bearing 3-functionalized pyrazole-linked 1,2,3-triazole derivatives as dual inhibitors of cathepsin B and carbonic anhydrase enzymes are reported. The target 1,2,3-triazole-linked pyrazolic esters (16) were synthesized by the condensation of 1,2,3-triazolic diketo esters with 4-hydrazinobenzenesulfonamide hydrochloride, and these were further converted into the corresponding carboxylic acid (17) and carboxamide (18) analogs. The synthesized compounds were assayed in vitro for their inhibition potential against human carbonic anhydrase (hCA) isoforms I, II, IX, and XII. They were found to be potent inhibitors at the low nanomolar level against the cancer-related hCA IX and XII and to be selective towards the cytosolic isoform hCA I. The physiologically important isoform hCA II was potently inhibited by all the newly synthesized compounds showing KI values ranging between 0.8 and 561.5 nM. The ester derivative 16c having 4-fluorophenyl (KI = 5.2 nM) was the most potent inhibitor of hCA IX, and carboxamide derivative 18b (KI = 2.2 nM) having 4-methyl substituted phenyl was the most potent inhibitor of hCA XII. The newly synthesized compounds exhibited potent cathepsin B inhibition at 10-7 M concentration. In general, the carboxamide derivatives (18) showed higher % inhibition as compared with the corresponding ester derivatives (16) and carboxylic acid derivatives (17) for cathepsin B. The interactions of the target compounds with the active sites of cathepsin B and CA were studied through molecular docking studies. Further, the in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) and drug-likeness properties of the target compounds were also studied.
RESUMEN
Herein, we report the design and synthesis of a library of 28 new 1,2,3-triazole derivatives bearing carboxylic acid and ester moieties as dual inhibitors of carbonic anhydrase (CA) and cathepsin B enzymes. The synthesised compounds were assayed in vitro for their inhibition potential against four human CA (hCA) isoforms, I, II, IX and XII. The carboxylic acid derivatives displayed low micromolar inhibition against hCA II, IX and XII in contrast to the ester derivatives. Most of the target compounds showed poor inhibition against the hCA I isoform. 4-Fluorophenyl appended carboxylic acid derivative 6c was found to be the most potent inhibitor of hCA IX and hCA XII with a KI value of 0.7 µM for both the isoforms. The newly synthesised compounds showed dual inhibition towards CA as well as cathepsin B. The ester derivatives exhibited higher % inhibition at 10-7 M concentration as compared with the corresponding carboxylic acid derivatives against cathepsin B. The results from in silico studies of the target compounds with the active site of cathepsin B were found in good correlation with the in vitro results. Moreover, two compounds, 5i and 6c, showed cytotoxic activity against A549 lung cancer cells, with IC50 values lower than 100 µM.
Asunto(s)
Anhidrasas Carbónicas , Ácidos Carboxílicos , Humanos , Ácidos Carboxílicos/farmacología , Ésteres/farmacología , Inhibidores de Anhidrasa Carbónica/farmacología , Catepsina B , Relación Estructura-Actividad , Triazoles/farmacología , Isoformas de ProteínasRESUMEN
Enzymes are the biological macromolecules that have emerged as an important drug target as their upregulation/imbalance leads to various pathological conditions, such as inflammation, parasitic infection, Alzheimer's, cancer, and many others. Here, we designed and synthesized some morpholine tethered novel aurones and evaluated them as potential inhibitors for CTSB, α-amylase, lipase and activator for trypsin. All the newly synthesized compounds were fully characterized by various spectroscopic techniques (1H NMR, 13C NMR, HRMS) and the Z-configuration to them was assigned based on single crystal XRD data and 1H NMR chemical shift values. Further, the hybrids were evaluated for their intracellular (cathepsin B) and extracellular (trypsin, lipase, amylase) enzyme inhibition potencies. The in-vitro inhibition screening against cathepsin B revealed that most of the synthesized compounds are good competitive inhibitors (% inhibition = 22.91-75.04), with 6q (% inhibition = 75.04) and 6r (% inhibition = 71.13) as the eminent inhibitors of the series. At the same time, they exhibited weak to moderate inhibition towards amylase (% inhibition = 7.22-22.48) and lipase (% inhibition = 16.29-54.83). A significant trypsin activation (% activation = 107.42-196.47) was observed even at the micromolar concentration of the compounds. Furthermore, the drug-modeling studies showed a good correlation between the in-vitro experimental results and the calculated binding affinity of the screened compounds with all the tested enzymes. These findings are expected to provide a new lead in drug development for different pathological disorders wherever these enzymes are involved.
Asunto(s)
Catepsina B , Morfolinas , Simulación del Acoplamiento Molecular , Tripsina , Morfolinas/farmacología , Amilasas , LipasaRESUMEN
Twenty-one novel extended analogs of acetazolamide were synthesized and screened in vitro for their inhibition efficacy against human carbonic anhydrase (hCA) isoforms I, II, IX, XII, and cathepsin B. The majority of the compounds were found to be effective inhibitors of tumor-associated hCA IX and XII, and poor inhibitors of cytosolic hCA I. Despite the strong to moderate inhibition potential possessed by these compounds toward another cytosolic isoform hCA II, some of them demonstrated better potency against hCA IX and/or XII isoforms as compared to hCA II. Four compounds (11f, 11g, 12c, and 12g) effectively inhibited hCA IX and/or XII isoforms with considerable selectivity over the off-targets hCA I and II. Interestingly, five compounds, including 11f, 11g, 12c, 12d, and 12g, inhibited hCA IX even better than the clinically used acetazolamide. Some of the novel synthesized compounds exhibited higher anti-cathepsin B potential than acetazolamide, with % inhibition of around 50%, at a concentration of 10-7 M. Further, two compounds (12g and 12c) that showed effective and selective inhibition activity profiles against hCA IX and XII were additionally found to be effective inhibitors of cathepsin B.
Asunto(s)
Anhidrasas Carbónicas , Neoplasias , Humanos , Anhidrasas Carbónicas/metabolismo , Acetazolamida/farmacología , Catepsina B , Relación Estructura-Actividad , Inhibidores de Anhidrasa Carbónica/farmacología , Anhidrasa Carbónica I , Isoformas de Proteínas , Estructura MolecularRESUMEN
Curcumin, a molecule of immense pharmacological significance is also known to exhibit poor aqueous solubility and low bioavailability. Different strategies have been adopted to enhance the aqueous solubility of curcumin, but report on the effect of traditional excipients on curcumin solubility still stand in need of. Here, we presented the significance of different traditional excipients used in anti-inflammatory formulations on curcumin solubility. The endeavor has been undertaken with the hypothesis that "traditional formulation used since ages have a scientific basis". To meet the quest we encapsulated 28 different formulations containing varying concentrations of milk, sugar, cow milk fat, and black pepper in alginate hydrogels. After the characterization of formulations through FT-IR, solubility studies were conducted. Milk was found to be an essential component for improved curcumin availability. Individually, cow milk fat and piperine exhibited lesser effect but their synergistic effect was observed in the presence of milk. Dual behavior of sugar has been observed. Traditionally used excipients greatly enhanced the solubility of curcumin. The results have also been validated through anti-oxidant activities of different formulations. Intermolecular interactions have been explained using Molecular modeling studies.
Asunto(s)
Alginatos/química , Antioxidantes/química , Curcumina/química , Excipientes/química , Hidrogeles/química , Alcaloides/química , Animales , Benzodioxoles/química , Curcuma/química , Liberación de Fármacos , Leche/química , Modelos Moleculares , Piperidinas/química , Alcamidas Poliinsaturadas/química , Solubilidad , Sacarosa/químicaRESUMEN
Cathepsins have emerged out as significant targets in variety of tissue degenerative disorders such as inflammation, alzeimers, tumerogenesis including metastasis and invasion. Elevated levels of cathepsins and reduced cellular inhibitors at the site of these diseased conditions suggest the exploration of novel inhibitors of cathepsins. In the search of effective novel inhibitors as anti-cathepsin agents different natural products are also screened. One such molecule, curcumin has been reported as potential anti-cathepsin agent in recent past. Low solubility of curcumin makes it an important subject for screening effect of different pharmaceutical excipients toward enhanced solubility. In the present work we report serum protein protecting and anti-cathepsin activities of 28 different formulations of curcumin. The formulations have been prepared using four ingredients used in traditional medicinal system. Milk has been found to enhance solubility to a significant level. Cow milk fat, sucrose and piperine exhibited positive cooperation. The results have been explained on the basis of chemical behavior of different ingredients.
Asunto(s)
Catepsina B/antagonistas & inhibidores , Catepsina H/antagonistas & inhibidores , Curcumina/farmacología , Inhibidores Enzimáticos/farmacología , Sustancias Protectoras/farmacología , Albúmina Sérica Bovina/metabolismo , Animales , Catepsina B/metabolismo , Catepsina H/metabolismo , Bovinos , Curcumina/síntesis química , Curcumina/química , Relación Dosis-Respuesta a Droga , Composición de Medicamentos , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/química , Cabras , Modelos Moleculares , Estructura Molecular , Sustancias Protectoras/síntesis química , Sustancias Protectoras/química , Relación Estructura-ActividadRESUMEN
Cathepsins have emerged as important targets in various tissues degenerative disorders due to their involvement in degradation of extracellular matrices and endogenous protein turnover. Elevated cathepsins levels vis-à-vis decreased concentration of endogenous inhibitors has been reported at different diseased sites. The design and synthesis of specific potential anti-cathepsin agents is therefore of great significance. Most of potential anti-cathepsin agents developed have peptide based structures with an active warhead. Due to oral instability and immunogenic problems related to peptidyl inhibitors drift the synthesis and evaluation of non-peptide cathepsin inhibitors in last two decades. The present work provides a detailed structure activity relationship for developing potential non-peptide anticathepsin agents based on in-vitro inhibition studies of a library of synthesized thiocarbamoyl- non-peptide inhibitors.
Asunto(s)
Catepsina B/antagonistas & inhibidores , Catepsina H/antagonistas & inhibidores , Catepsina L/antagonistas & inhibidores , Inhibidores de Proteasas/farmacología , Tiocarbamatos/farmacología , Catepsina B/aislamiento & purificación , Catepsina B/metabolismo , Catepsina H/aislamiento & purificación , Catepsina H/metabolismo , Catepsina L/aislamiento & purificación , Catepsina L/metabolismo , Relación Dosis-Respuesta a Droga , Humanos , Estructura Molecular , Inhibidores de Proteasas/síntesis química , Inhibidores de Proteasas/química , Relación Estructura-Actividad , Tiocarbamatos/síntesis química , Tiocarbamatos/químicaRESUMEN
Cathepsins have emerged as promising molecular targets in a number of diseases such as Alzeimer's, inflammation and cancer. Elevated cathepsin's levels and decreased cellular inhibitor concentrations have emphasized the search for novel inhibitors of cathepsins. The present work is focused on the design and synthesis of some acetophenone phenylhydrazone based pyrazole derivatives as novel non peptidyl inhibitors of cathepsins B, H and L. The synthesized compounds after characterization have been explored for their inhibitory potency against cathepsins B, H and L. The results show that some of the synthesized compounds exhibit anti-catheptic activity with Ki value of the order of 10-10M. Differential inhibitory effects have been observed for cathepsins B, H and L. Cathepsin L is inhibited more pronounced than cathepsin B and cathepsin H in that order.
Asunto(s)
Acetofenonas/química , Catepsinas/antagonistas & inhibidores , Hidrazonas/química , Inhibidores de Proteasas/química , Pirazoles/química , Sitios de Unión , Dominio Catalítico , Catepsina B/antagonistas & inhibidores , Catepsina B/metabolismo , Catepsina H/antagonistas & inhibidores , Catepsina H/metabolismo , Catepsina L/antagonistas & inhibidores , Catepsina L/metabolismo , Catepsinas/metabolismo , Cinética , Simulación del Acoplamiento Molecular , Inhibidores de Proteasas/síntesis química , Inhibidores de Proteasas/metabolismo , Pirazoles/síntesis química , Pirazoles/metabolismo , Relación Estructura-ActividadRESUMEN
High levels of cathepsins indicated in various pathological conditions like arthritis, cancer progressions, and atherosclerosis explains the need to explore potential inhibitors of these proteases which can be of great therapeutic significance. We, in the present work, report the synthesis of some 2,5-diaryloxadiazoles from N-subsitutedbenzylidenebenzohydrazides. The synthesized compounds were screened for their inhibitory potential on cathepsins B, H and L. Structure Activity Relationship studies show that 2,5-diaryloxadiazoles were less inhibitory than their precursors. 1i and 2k have been found to be most inhibitory to cathepsins B and L. Their Ki values have been calculated as 11.38×10(-8)M and 66.4×10(-8)M for cathepsin B and 4.2×10(-9)M and 47.31×10(-9)M for cathepsin L, respectively. However, cathepsin H activity was maximally inhibited by compounds, 1e and 2c with Ki values of 4.4×10(-7)M and 5.6×10(-7)M, respectively. Enzyme kinetic studies suggest that these compounds are competitive inhibitors to the enzymes. The results have been compared with docking results obtained using iGemDock.
Asunto(s)
Catepsina B/antagonistas & inhibidores , Catepsina H/antagonistas & inhibidores , Catepsina L/antagonistas & inhibidores , Oxadiazoles/farmacología , Inhibidores de Proteasas/farmacología , Animales , Catepsina B/metabolismo , Catepsina H/metabolismo , Catepsina L/metabolismo , Relación Dosis-Respuesta a Droga , Cabras , Hígado/enzimología , Simulación del Acoplamiento Molecular , Estructura Molecular , Oxadiazoles/síntesis química , Oxadiazoles/química , Inhibidores de Proteasas/síntesis química , Inhibidores de Proteasas/química , Relación Estructura-ActividadRESUMEN
A direct correlation between cathepsin expression-cancer progression and elevated levels of cathepsins due to an imbalance in cellular inhibitors-cathepsins ratio in inflammatory diseases necessitates the work on the identification of potential inhibitors to cathepsins. In the present work we report the synthesis of some 2,3-dihydroquinazolin-4(1H)-ones followed by their evaluation as cysteine protease inhibitors in general and cathepsin B and cathepsin H inhibitors in particular. 2,3-Dihydroquinazolin-4(1H)-ones, synthesized by the condensation of anthranilamide and carbonyl compound in presence of PPA-SiO2 catalyst, were characterized by spectral analysis. The designed compounds were screened as inhibitors to proteolysis on endogenous protein substrates. Further, a distinct differential pattern of inhibition was obtained for cathepsins B and H. The inhibition was more to cathepsin B with Ki values in nanomolar range. However, cathepsin H was inhibited at micromolar concentration. Maximum inhibition was shown by compounds, 1e and 1f for cathepsin B and compounds 1c and 1f for cathepsin H. The synthesized compounds were established as reversible inhibitors of cathepsins B and H. The results were also compared with the energy of interaction between enzyme active site and compounds using iGemdock software.
Asunto(s)
Catepsina B/antagonistas & inhibidores , Catepsina H/antagonistas & inhibidores , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacología , Quinazolinonas/química , Quinazolinonas/farmacología , Animales , Catepsina B/aislamiento & purificación , Catepsina B/metabolismo , Catepsina H/aislamiento & purificación , Catepsina H/metabolismo , Cabras , Hígado/enzimología , Modelos Moleculares , Proteolisis/efectos de los fármacosRESUMEN
Cathepsins have emerged as potential drug targets for melanoma therapy and engrossed attention of researchers for development and evaluation of cysteine cathepsin inhibitors as cancer therapeutics. In this direction, we have designed, synthesized, and assayed in vitro a small library of 30 low molecular weight functionalized analogs of chalcone hydrazones for evaluating structure-activity relationship aspects and inhibitory potency against cathepsin B and H. The maximum inhibitory effect was exerted by chalcone hydrazones, which are open chain analogues followed by their cyclized derivatives, pyrazolines and pyrazoles. All the synthesized compounds were established as reversible inhibitors of these enzymes. Cathepsin B was selectively inhibited by the compounds in each series. Compounds 1d, 2d and 4d were recognized as most potent inhibitors of cathepsin B in this study with Ki values of 0.042 µM, 0.053 µM and 0.131 µM whereas 1b (Ki=1.111 µM), 2b (Ki=1.174 µM) and 4b (Ki=1.562 µM) inhibited cathepsin H activity effectively. And, preeminent cathepsin B inhibitors were -NO2 functionalized however, -Cl substituted moieties were the most persuasive inhibitors for cathepsin H among all the designed compounds. Molecular docking studies performed using iGemdock provided valuable insights.
Asunto(s)
Catepsina B/antagonistas & inhibidores , Catepsina H/antagonistas & inhibidores , Chalconas/química , Hidrazonas/química , Inhibidores de Proteasas/química , Animales , Sitios de Unión , Dominio Catalítico , Catepsina B/metabolismo , Catepsina H/metabolismo , Chalconas/síntesis química , Chalconas/metabolismo , Ciclización , Humanos , Cinética , Simulación del Acoplamiento Molecular , Inhibidores de Proteasas/síntesis química , Inhibidores de Proteasas/metabolismo , Unión Proteica , Relación Estructura-ActividadRESUMEN
The emergence of cathepsins as a potential target for anticancer drugs has led to extensive research in the development of their inhibitors. In the present study, we designed, synthesized, and characterized several cinnamaldehyde schiff bases employing diverse hydrazines, as potential cathepsin B inhibitors. The parallel studies on cathepsin B isolated from liver and cerebrospinal fluid unveiled the significance of the synthesized compounds as cathepsin B inhibitors at nanomolar concentrations. The compound, 7 exhibited the highest inhibition of 83.48 % and 82.96 % with an IC50 value of 0.06 nM and 0.09 nM for liver and cerebrospinal fluid respectively. The inhibitory potential of synthesized compounds has been extremely effective in comparison to previous reports. With the help of molecular docking studies using iGEMDOCK software, we found that the active site -CH2SH group is involved in the case of α-N-benzoyl-D, l-arginine-b-naphthylamide (BANA), curcumin 2, 3, 6, and 7. For toxicity prediction, ADMET studies were conducted and the synthesized compounds emerged to be non-toxic. The results obtained from the in vitro studies were supported with in silico studies. The synthesized cinnamaldehyde schiff bases can be considered promising drug candidates in conditions with elevated cathepsin B levels.
Asunto(s)
Acroleína , Catepsina B , Hidrazonas , Hígado , Simulación del Acoplamiento Molecular , Catepsina B/antagonistas & inhibidores , Catepsina B/metabolismo , Acroleína/análogos & derivados , Acroleína/química , Acroleína/farmacología , Hígado/efectos de los fármacos , Hígado/metabolismo , Humanos , Hidrazonas/farmacología , Hidrazonas/química , Hidrazonas/síntesis química , Dominio Catalítico , AnimalesRESUMEN
Background: Exploration of the multi-target approach considering both human carbonic anhydrase (hCA) IX and XII and cathepsin B is a promising strategy to target cancer. Methodology & Results: 22 novel 1,2,4-triazole derivatives were synthesized and evaluated for their inhibition efficacy against hCA I, II, IX, XII isoforms and cathepsin B. The compounds demonstrated effective inhibition against hCA IX and/or XII isoforms with considerable selectivity over off-target hCA I/II. All compounds presented significant anticathepsin B activities at a low concentration of 10-7 M and in vitro results were also supported by the molecular modeling studies. Conclusion: Insights of present study can be utilized in the rational design of effective and selective hCA IX and XII inhibitors capable of inhibiting cathepsin B.
[Box: see text].
Asunto(s)
Inhibidores de Anhidrasa Carbónica , Catepsina B , Triazoles , Inhibidores de Anhidrasa Carbónica/farmacología , Inhibidores de Anhidrasa Carbónica/química , Inhibidores de Anhidrasa Carbónica/síntesis química , Humanos , Triazoles/química , Triazoles/farmacología , Triazoles/síntesis química , Catepsina B/antagonistas & inhibidores , Catepsina B/metabolismo , Relación Estructura-Actividad , Anhidrasas Carbónicas/metabolismo , Estructura Molecular , Simulación del Acoplamiento Molecular , Modelos MolecularesRESUMEN
In the present work chemical transformation of carboxymethylcellulose with curcumin in ester form has led to the development of target specific sustained release delivery system for curcumin in presence of liver esterases. We here report synthesis, characterizations (FTIR, SEM and XRD) curcumin-carboxymethylcellulose ester (Cur-CMC ester) and its target specific hydrolysis to release curcumin. Cur-CMC ester has been found stable when simulated in-vitro in gastric fluid (pH 1.2) and in intestinal fluid (pH 6.8). On in-vitro simulation in liver homogenate curcumin is released from Cur-CMC ester after hydrolysis in a consistent amount (â¼43 %) for 5 h. The release of curcumin from ester was highest at pH 8.0 in presence of liver enzymes. The present study suggested that modified CMC support can not only be used for the delivery of curcumin in liver but also acts as prodrug system and released free curcumin in presence of liver esterases.
Asunto(s)
Curcumina , Nanopartículas , Curcumina/química , Carboximetilcelulosa de Sodio , Preparaciones de Acción Retardada , Portadores de Fármacos/química , Hígado , Nanopartículas/químicaRESUMEN
In the realm of enzymes, the Enzyme Immobilization technique can be extremely beneficial. More research into computational approaches could lead to a better understanding as well as lead us in the direction of a more environmentally friendly and greener path. In this study, molecular modelling techniques were used to collect information regarding the immobilization of Lysozyme (EC 3.2.1.17) on Dialdehyde Cellulose (CDA). Lysine, being the most nucleophilic, is most likely to interact with dialdehyde cellulose. Enzyme substrate interactions have been studied with and without the refinement of modified lysozyme molecules. A total of six CDA-modified lysine residues were selected for the study. The docking process for all modified lysozymes was carried out using four distinct docking programs: Autodock Vina, GOLD, Swissdock, and iGemdock. The binding affinity (-7.8 & -8.0 kcal mol-1 in case of non-refinement and -4.7 & -5.0 kcal mol-1 in case of refinement), calculated from Autodock vina, as well as the interaction similarity of Lys116 immobilized lysozyme with its substrate, were found to be 75 % (W/o simulation) & 66.7 % (With simulation) identical with the reference case (unmodified lysozyme) if Lys116 is bound to Dialdehyde Cellulose. The approach described here is utilized to identify amino acid residues that are used in the immobilization of lysozyme.
Asunto(s)
Lisina , Muramidasa , Muramidasa/química , Lisina/metabolismo , Enzimas Inmovilizadas/química , Celulosa/química , Simulación del Acoplamiento MolecularRESUMEN
Use of natural polymer in the development of Drug Delivery Systems (DDS) has greatly increased in recent past because of their biocompatible, non-allergic and biodegradable nature. Natural polymers are usually hydrophilic supports, so in order to be a carrier of a hydrophobic drug their nature needs to be changed. Each developed system behaves differently towards different drugs in terms of loading and sustained release of the drug as well. In the present work we report differential binding of piperine & curcumin with cetyltrimethylammonium bromide (CTAB) modified cellulose, alginate and pectin. Difference in interaction between the piperine and curcumin with supports has been visualized using in-vitro as well as in-silico studies. Initial results obtained after in-silico studies have been validated via time dependent anti-trypsin, serum protein binding, anti-cathepsin, anti-oxidant, and anti-α-amylase activities. FT-IR, SEM, fluorescence and Particle size have been used to characterize the piperine loaded on CTAB-modified polymeric supports.
Asunto(s)
Curcumina , Curcumina/farmacología , Curcumina/química , Cetrimonio , Alginatos/química , Pectinas , Espectroscopía Infrarroja por Transformada de Fourier , Celulosa/química , Polímeros/química , Portadores de Fármacos/químicaRESUMEN
Background: Inhibition of human carbonic anhydrase (hCA) isoforms IX and XII with concurrent inhibition of cathepsin B is a promising approach for targeting cancers. Methods/results: 28 keto-bridged dual triazole-containing benzenesulfonamides were synthesized and tested, following the multitarget approach, for their efficacy as inhibitors of cathepsin B and hCA isoforms (I, II, IX, XII). The synthesized compounds showed excellent inhibition of CA isoforms (IX and XII) and cathepsin B. Compound 8i exhibited better and more selective inhibition of the cancer-associated isoform hCA IX as compared with acetazolamide (reference drug) and SLC-0111 (potent lead as carbonic anhydrase inhibitor). Molecular docking studies were also carried out. Conclusion: The present work gives important generalizations for the development of isoform-selective hCA inhibitors endowed with anti-cathepsin properties.